LiVeritas Biosciences

What LiVeritas Biosciences does

LiVeritas Biosciences is a private biotech company founded in 2020/2021 and headquartered in South San Francisco, California. The company provides AI-powered molecular testing services and software to biopharmaceutical and biotechnology clients, with a focus on mass spectrometry workflows supporting FDA regulatory submissions, IND filings, and drug development milestones including Phase 1 trials and contract manufacturing confirmation.

Its core technology centers on the LiLii™ Platform, a SaaS laboratory ecosystem that centralizes project management, CRM, document control, and analytics for drug development workflows, and the AI Co-Scientist suite of five specialized agents: Sylvia (Sequence Variant Analysis), Petra (Post-Translational Modification tracking), Irma (Intact Mass profiling), Gian (Glycan characterization), and Desmond (Disulfide Bond Mapping). These agents automate structural analysis across complex biologic modalities, with company-reported performance claims including 70% reduction in manual analyst time, 3x weekly testing capacity increase, and 15x faster data processing.

The company generates revenue through usage-based pricing for molecular testing services (peptide mapping, intact mass analysis, glycan characterization) and SaaS subscriptions to the LiLii™ platform. Pricing is quote-based across four tiers ranging from Starter (100 tests annually) through CRO Partner (10,000+ tests). The company employs 1-10 people and serves both enterprise biopharma companies and earlier-stage biotech startups through direct enterprise sales targeting Heads of CMC, Chief Scientific Officers, and Protein Science directors.

Name

LiVeritas Biosciences

Legal name

LiVeritas Biosciences, Inc.

Website

https://liveritas.bio

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

LiVeritas Biosciences is a private biotech company that provides AI-powered molecular testing services and the LiLii™ SaaS platform for FDA-grade mass spectrometry workflows, serving biopharma and biotech companies across drug development and regulatory submission stages.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Analytical Testing Services

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511), Testing Laboratories and Services (54138), Testing Laboratories and Services (541380)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Molecular testing services
• Mass spectrometry workflows
• Biopharma analytical testing
• AI laboratory platform
• FDA-grade drug development

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Molecular Testing Services: Usage-based pricing for analytical testing services including peptide mapping, intact mass analysis, glycan characterization, and other mass spectrometry workflows. Clients purchase test packages ranging from 100 to 10,000+ tests annually.
2. AI Co-Scientist Platform Subscription: SaaS platform providing AI-powered laboratory ecosystem with project management, CRM, document control, and analytics capabilities for drug development workflows.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

LiVeritas Biosciences delivers FDA-grade molecular testing services for biopharma drug development, using AI-augmented mass spectrometry workflows for peptide mapping, sequence variant analysis, post-translational modification tracking, intact mass profiling, glycoform characterization, and disulfide bond mapping. The company backs these services with its proprietary LiLii™ SaaS platform and a suite of specialized AI Co-Scientist agents that automate structural analysis and centralize project management, CRM, and document control. Clients purchase usage-based test packages (100 to 10,000+ tests annually) and receive audit-ready, regulatory-grade outputs in under five days.

Product overview

LiVeritas Biosciences offers a unified platform architecture centered on the LiLii™ Platform, an integrated laboratory ecosystem powered by proprietary AI. The core product is the AI Co-Scientist Platform comprising five specialized AI agents (Sylvia for Sequence Variant Analysis, Petra for PTM tracking, Irma for Intact Mass profiling, Gian for Glycan characterization, and Desmond for Disulfide Map analysis) that work in tandem to automate structural analysis across biologic modalities. This platform-plus-agent architecture enables biopharma clients to process molecular testing data 15x faster, with claims of 70% manual time eliminated and 3x weekly testing capacity increase.

Differentiator

Problem solved

Functional benefit

Brands

• LiLii™ Platform: AI-powered integrated laboratory ecosystem SaaS platform that centralizes project management, CRM, document control, and analytics for drug development workflows, enabling data processing 15x faster with greater accuracy and transparency.
• AI Co-Scientist
• Sylvia (SVA)
• Petra (PTM)
• Irma (Intact Mass)
• Gian (Glycans)
• Desmond (Disulfide Map)

Products and services

• LiLii™ Platform AI-powered integrated laboratory ecosystem SaaS platform that centralizes project management, CRM, document control, and analytics for biopharma drug development workflows, processing data 15x faster with greater accuracy and transparency. Built for compliance with audit-ready defaults and accelerated science delivery.
• AI Co-Scientist Platform Integrated suite of specialized AI agents (Sylvia for Sequence Variant Analysis, Petra for Post-Translational Modification tracking, Irma for Intact Mass profiling, Gian for Glycoform characterization, and Desmond for Disulfide Bond Mapping) that automate structural analysis across complex biologic modalities, eliminating manual data entry and scaling biopharma testing throughput.
• Molecular Testing Services FDA-grade mass spectrometry analytical testing services for biopharma clients, covering peptide mapping, intact mass analysis, glycan characterization, sequence variant analysis, post-translational modification analysis, and disulfide bond mapping. Sold as usage-based test packages ranging from 100 to 10,000+ tests annually, with FDA-ready output delivered in under five days.

Quantifiable outcome

• 70% of manual time eliminated in molecular testing workflows
• +5 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/liveritas
• LinkedInlinkedin.com/company/liveritas-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LiVeritas Biosciences